PKMYT1 Inhibition as a Therapeutic Strategy in Triple-Negative Breast Cancer
Khandan Keyomarsi shared on X:
“Exciting work from our lab reporting that TNBCs that do not respond to chemotherapy have high LMW-E levels that upregulates and stabilizes PKMYT1, leading to enhanced p-CDK1 in TNBCs, which are now more sensitive to the PKMYT1 inhibitor RP-6306.”
Authors: Mi Li, Amriti R. Lulla, Yan Wang, Spyros Tsavachidis, Fuchenchu Wang, Cansu Karakas, Tuyen D.T. Nguyen, Tuyen N. Bui, Marc A. Pina, Mei-Kuang Chen, Sofia Mastoraki, Asha S. Multani, Natalie W. Fowlkes, Aysegul Sahin, C. Gary. Marshall, Kelly K. Hunt, Khandan Keyomars
Source: Khandan Keyomarsi/X
For more posts about breast cancer, visit oncodaily.com
Khandan Keyomarsi, Ph.D. is the Professor in the Department of Experimental Radiation Oncology in the Division of Radiation Oncology at The University of Texas MD Anderson Cancer Center, Houston. She is also the William C. Liedtke, Jr. Chair in Cancer Research at The University of Texas MD Anderson Cancer Center. She is the Founder and Director of TRIUMPH, Translational Research in Multi-Disciplinary Programs for post-doctoral fellows.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023